Ew Healthcare Partners Fund 2, Purchases 13,087 Shares of TELA Bio, Inc. (NASDAQ:TELA) Stock

TELA Bio, Inc. (NASDAQ:TELA) insider Ew Healthcare Partners Fund 2, bought 13,087 shares of the firm’s stock in a transaction that occurred on Thursday, September 9th. The stock was purchased at an average cost of $12.46 per share, with a total value of $163,064.02. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ew Healthcare Partners Fund 2, also recently made the following trade(s):

  • On Tuesday, September 7th, Ew Healthcare Partners Fund 2, bought 131 shares of TELA Bio stock. The stock was purchased at an average cost of $12.77 per share, with a total value of $1,672.87.

Shares of TELA Bio stock opened at $12.29 on Wednesday. The business has a fifty day simple moving average of $14.05 and a two-hundred day simple moving average of $14.18. TELA Bio, Inc. has a 1 year low of $11.03 and a 1 year high of $18.00. The company has a market capitalization of $177.86 million, a price-to-earnings ratio of -5.59 and a beta of 1.92. The company has a debt-to-equity ratio of 0.89, a current ratio of 9.70 and a quick ratio of 9.08.

TELA Bio (NASDAQ:TELA) last announced its quarterly earnings results on Tuesday, August 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.05). TELA Bio had a negative net margin of 130.59% and a negative return on equity of 70.07%. The business had revenue of $7.56 million for the quarter, compared to analyst estimates of $6.40 million. As a group, equities analysts anticipate that TELA Bio, Inc. will post -2.23 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new stake in shares of TELA Bio during the first quarter worth $266,000. Renaissance Technologies LLC acquired a new stake in shares of TELA Bio during the first quarter worth $432,000. Geode Capital Management LLC lifted its holdings in shares of TELA Bio by 1.7% during the first quarter. Geode Capital Management LLC now owns 97,567 shares of the company’s stock worth $1,453,000 after buying an additional 1,634 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of TELA Bio by 1.8% during the first quarter. BlackRock Inc. now owns 312,282 shares of the company’s stock worth $4,653,000 after buying an additional 5,636 shares in the last quarter. Finally, Pura Vida Investments LLC lifted its holdings in shares of TELA Bio by 36.2% during the first quarter. Pura Vida Investments LLC now owns 421,202 shares of the company’s stock worth $6,276,000 after buying an additional 111,879 shares in the last quarter. 72.12% of the stock is owned by institutional investors and hedge funds.

Separately, Zacks Investment Research cut shares of TELA Bio from a “hold” rating to a “sell” rating in a research note on Thursday, August 5th.

About TELA Bio

TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Featured Story: Intrinsic Value

Insider Buying and Selling by Quarter for TELA Bio (NASDAQ:TELA)

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.